

SYVA announces its partnership with the biotech SMIVET for the development of single-domain antibody-based solutions in animal health.

León - Technology Park - Spain, March 2, 2023 - SYVA and SMIVET signed a collaboration agreement that allow both companies to develop therapeutic solutions based on Single Domain Antibodies (SDA). With this agreement, Syva expresses its willingness to invest in new biotechnologies with the objective to continue to grow and improve its attractiveness by researching, developing, and producing innovative and meaningful solutions for the animal health sector.

By signing such a collaboration agreement* with the biotech company SMIVET, SYVA opens many new horizons in terms of developing targeted bio-therapeutic solutions in both the livestock and companion animal sectors.

Thanks to regular investments over the years, Syva is well equipped with state-of-the-art facilities and ensures that all stages of the development and production of its veterinary medicines are within the best practices. This is achieved primarily by researching and analysing development opportunities within its R&D department.

"To ensure that we remain competitive and attractive in our sector of activity, we must continue to be committed to researching, innovating and investing in new technological development of our production sites. With this state of mind, we decided to focus on Single Domain Antibodies, and, after an in-depth analysis of our mutual development capabilities, we chose the biotech company SMIVET as partner and new driver of our strategic evolution," said César Carnicer, Managing Director of Syva Laboratories.

Since 2013, SMIVET has developed its own supportive SDA platform and its pipeline libraries enables the development of new biotherapeutics solutions to treat diseases in companion animals as well as in livestock.

"Single-domain antibodies or nanobodies, in addition to being a rapidly growing innovative field, offer many development opportunities in the treatment of a broad range of infectious, inflammatory, degenerative and chronic diseases in animals. Their small size, high specificity and low immunogenicity allow for many applications with high efficiency," said Dr (PHD) Hans de Smit.

SYVA and SMIVET, are both family-owned companies. Hans de Smit, Founder and Managing Director of SMIVET and César Carnicer, General Manager of SYVA, are both veterinarians with a strong veterinary pharmaceutical industry background and this collaboration is based on a strategic match.

*The terms of the transaction are not disclosed

ABOUT SMIVET

SMIVET BV is a veterinary biotech company founded in 2013 in the Netherlands. The R&D activities came up to speed from end of 2014 onwards when the company decided to focus on the technology of Single Domain Antibodies (SDAs) and develop a suitable supportive SDA platform for use in multiple animal species. Its actual research pipeline is based on several proprietary SDA libraries with the purpose to introduce new innovative bio-therapeutics for the treatment of diseased cats, dogs, horses, fish, and livestock.

The research efforts are supported by a network of specialists from academia and the industry.

For more information about SMIVET : <https://smivet.com>

ABOUT SYVA

Since its foundation in 1941, the Spanish company Laboratorios Syva has been committed to researching opportunities and to scientific based development to innovate and offer efficient solutions for the animal health sector. This capacity to adapt drives the company's strategy to grow and to maintain state-of-the-art bioengineering and manufacturing facilities to produce vaccines, first-line anti-infectives and other essential medicines for animal health and welfare, which are distributed in nearly 70 countries worldwide.

For more information about SYVA : <https://syva.es>

Contact Press Corporate communication:

Caroline De Siron
Corporate and digital communication
caroline.de.siron@syva.es